Raposeiras-Roubín, SergioAnguita, ManuelLatini, RobertoDomínguez-Rodríguez, AlbertoBarrabés, José ASánchez, Pedro LOttani, FilippoPocock, StuartOwen, RuthCristobo, PabloGómez-Talavera, SandraStaszewsky, LidiaEscalera, NoemíFernández-Vázquez, FelipeBianco, MatteoPrada-Delgado, ÓscarPérez-García, Carlos NicolásPelizzoni, ValentinaNavarro, FelipePérez-Rivera, José-ÁngelMartín-Gorria, GonzaloVetrano, AlfredoFuster, ValentínRosselló, XavierIbáñez, Borja2026-04-272026-04-272026-04-23Rev Esp Cardiol (Engl Ed). 2026 Apr 23:S1885-5857(26)00076-9.https://hdl.handle.net/20.500.12105/27446Recent trials have questioned the clinical benefit of beta-blockers in post-myocardial infarction (MI) patients with preserved left ventricular ejection fraction (LVEF). However, differences in pathophysiology and risk profile between MI with and without ST-segment elevation (STEMI and NSTEMI) may influence the effect of beta-blockers. In this prespecified subgroup analysis of the REBOOT trial, which randomized invasively managed MI patients with LVEF > 40% to beta-blockers or control, we evaluated differences in long-term effects of the intervention between STEMI (n = 4296) and NSTEMI (n = 4142). The primary endpoint was a composite of all-cause death, reinfarction, or heart failure hospitalization over a median follow-up of 3.7 years.REBOOT-CNIC was an independent trial funded by the Centro Nacional de Investigaciones Cardiovasculares (CNIC). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia, Innovación y Universidades and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by ICIU/AEI/10.13039/501100011033).engPhttp://creativecommons.org/licenses/by-nc-nd/4.0/Acute coronary syndromeBeta-blockersBloqueadores betaEnsayo clínico aleatorizadoIAMCESTIAMSESTNSTEMIRandomized controlled trialSTEMISíndrome coronario agudoAttribution-NonCommercial-NoDerivatives 4.0 International42034335REVISTA ESPAÑOLA DE CARDIOLOGIAopen access